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We show that the M2 isoform of pyruvate kinase (M2PYK) exists in
equilibrium between monomers and tetramers regulated by allo-
steric binding of naturally occurring small-molecule metabolites.
Phenylalanine stabilizes an inactive T-state tetrameric conformer
and inhibits M2PYKwith an IC50 value of 0.24mM,whereas thyroid
hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric
form of M2PYK with an IC50 of 78 nM. The allosteric activator fruc-
tose-1,6-bisphosphate [F16BP, AC50 (concentration that gives 50%
activation) of 7 μM] shifts the equilibrium to the tetrameric active R-
state, which has a similar activity to that of the constitutively fully
active isoform M1PYK. Proliferation assays using HCT-116 cells
showed that addition of inhibitors phenylalanine and T3 both in-
creased cell proliferation, whereas addition of the activator F16BP
reduced proliferation. F16BP abrogates the inhibitory effect of both
phenylalanine and T3, highlighting a dominant role of M2PYK
allosteric activation in the regulation of cancer proliferation. X-ray
structures show constitutively fully active M1PYK and F16BP-
bound M2PYK in an R-state conformation with a lysine at the
dimer-interface acting as a peg in a hole, locking the active tetra-
mer conformation. Binding of phenylalanine in an allosteric pocket
induces a 13° rotation of the protomers, destroying the peg-in-hole
R-state interface. This distinct T-state tetramer is stabilized by ﬂip-
ped out Trp/Arg side chains that stack across the dimer interface. X-
ray structures and biophysical binding data of M2PYK complexes
explain how, at a molecular level, ﬂuctuations in concentrations of
amino acids, thyroid hormone, and glucose metabolites switch
M2PYK on and off to provide the cell with a nutrient sensing and
growth signaling mechanism.
allosteric regulation | nutrient sensor | thyroid hormone T3 |
Warburg effect
The last of 10 enzymatic steps used to convert glucose to pyru-vate is carried out by pyruvate kinase (PYK), which transfers
a phosphate from phosphoenolpyruvate to ADP to generate ATP.
There are four human PYK isoforms (1); RPYK is restricted to
erythrocytes, LPYK is found predominantly in liver and kidney,
M1PYK is in muscle and brain, and M2PYK is found in fetal tis-
sues and in proliferating cells. All four isoforms are active as tet-
ramers; M1PYK is constitutively fully active, whereas R-, L-, and
M2PYKs are activated by the effector molecule fructose-1,6-
bisphosphate (F16BP) (2). M2PYK is a splice variant of the
nonallosteric M1PYK isoform and differs by 22 amino acid resi-
dues (3). Recent quantiﬁcation of the concentrations of consti-
tutively fully active M1PYK and allosterically regulated M2PYK
isoforms in both cancerous and control tissue samples has
revealed thatM2PYK is almost always the most abundant isoform
in cancer cells, although it can also be predominant in matched
control tissues (4). The up-regulation of the M2PYK isoform
plays a key role in cancer metabolism (3) and explains the War-
burg effect, in which proliferating cancer cells metabolize in-
creased amounts of glucose but with no increase in mitochondrial
oxidative phosphorylation (5). Regulation of M2PYK activity by
the allosteric effector F16BP provides a “metabolic budget sys-
tem” (6) to balance the energy requirements of the cell against the
requirements of a growing and dividing cell.
There are multiple allosteric feedback mechanisms at work
controlling the balance between the forward enzyme reaction (to
produce ATP and pyruvate) and M2PYK inhibition [resulting in
accumulation of intermediate metabolites required for DNA and
protein synthesis (7)]. There is a growing literature showing that
M2PYK activity can be modulated by acetylation (8), phosphor-
ylation (6, 9), cysteine oxidation (10), and proline hydroxylation
(11), providing additional mechanisms for enzyme regulation as
well as proffering recognition sites for a diverse range of protein
partners (6), including for example HIF (11), HPV E7 (12, 13),
and the peptide hormone somatostatin (14).
Switching on the production of the constitutively fully active
M1PYK was shown to reverse the Warburg effect and to inhibit
tumor growth in mouse xenograft models (3). This result suggests
that allosteric activation of M2PYK by pharmacological agents
could be of interest, and a number of potent activators have been
identiﬁed with AC50 (concentration that gives 50% activation)
values of approximately 30 nM (15, 16). Currently, the only
examples of isoenzyme-speciﬁc inhibitors are three families of
weak M2PYK inhibitors with IC50 values of 10–20 μM that show
some selectivity over M1PYK (17).
The results presented here show how M2PYK can be stabilized
in three biologically relevant states: an inactive monomer, a distinct
inactive T-state tetramer, and an active R-state tetramer (Fig. 1).
X-ray structures of the different states show how the tetramer
switches between the inactive T-state trapped as a phenylalanine
complex and the fully active R-state, which is very similar in
structure and enzyme activity to the constitutively fully active
M1PYK isoform. From a screen of more than 50 natural metabo-
lites, thyroid hormone triiodo-L-thyronine (T3) and phenylalanine
were identiﬁed as the strongest enzyme inhibitors. In cellular assays
we show that both T3 and phenylalanine increase cell proliferation,
whereas the addition of the allosteric activator F16BP decreased
cell proliferation. These enzymatic, structural, and cellular results
provide plausible molecular mechanisms linking cell proliferation
with allosteric regulation of M2PYK enzyme activity.
Results and Discussion
M2PYK Exists in Equilibrium Between Inactive Monomer and Active
Tetramer. Analytical gel ﬁltration was used to analyze the oligo-
meric natures of M1PYK and M2PYK. In the absence or pres-
ence of the allosteric effector F16BP, M1PYK eluted as a single
species with a retention volume of 1.3 mL (Fig. 2A), consistent
with M1PYK existing only as a tetramer. Under identical
conditions (0.1 mg mL−1) M2PYK eluted as a mixed population of
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tetramer, dimer, and monomer in the absence of F16BP (Fig.
2B). Peaks corresponding to tetramer and monomer could be
clearly assigned, whereas the putative dimer peak was poorly
resolved. Deconvolution of the peaks gave an estimate of the
molar ratios of tetramer (10%), dimer (10%), and monomer
(80%). (Percentages correspond to molar ratios of the oligomers
in the absence of F16BP.)
Size-exclusion chromatography coupled with multiangle light
scattering (SEC-MALS) was also used to measure molecular
masses for M2PYK forms (Fig. 2C). The initial large peak cor-
responds to the tetramer with a molecular mass of 214 kDa, and
a second smaller peak at 53 kDa is the monomeric form. The
analytical gel ﬁltration and SEC-MALS results thus provide in-
dependent conﬁrmation of tetrameric and monomeric M2PYK
forms. The gel chromatography trace from the latter technique
showed a poorly resolved peak that eluted between the monomer
and tetramer peaks, which is consistent with a small amount of
the M2PYK dimer; however, the resolution of the column used
for SEC-MALS was not sufﬁcient to measure its molecular mass
unambiguously.
Kinetic proﬁles of M1PYK and M2PYK were determined for
phosphoenolpyruvate (PEP) in the presence or absence of the
allosteric effector F16BP at 37 °C and are summarized in Table 1.
Using PEP as a substrate (without effector) M1PYK has an ap-
parent Vmax value of 346 μmol per min per mg and an S0.5(PEP) =
0.05 mM; addition of the effector F16BP made essentially no
difference to the kinetics. By contrast, addition of effector F16BP
to M2PYK resulted in a nearly twofold increase in apparent Vmax
(Fig. 2D) and a marked shift in the S0.5(PEP) value from 0.9 to
0.1 mM, with a concomitant drop in cooperativity (from a nH of
1.2 to 1.0). PEP cellular concentrations are estimated to lie be-
tween 0.02 and 0.5 mM (18). Activation of M2PYK by F16BP
would therefore increase reaction rates by between four- and 10-
fold over this PEP concentration range. For a given protein
concentration (∼0.03 μM), an increase in F16BP concentration
(from ∼2 μM to 30 μM) results in marked changes in apparent
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Fig. 1. Allosteric nutrient sensing mechanism also regulates cellular pro-
liferation. X-ray structures of the tetrameric Phe-bound T-state (B) and F16BP-
activated R-state (D) are shown as cartoons, with each 50-kDa protomer rep-
resented by a rectangular shape showing the effector and active sites. M2PYK
exists in equilibrium between tetrameric (C) and enzymatically inactive mono-
mer (A) forms (gray arrows). Phenylalanine (Phe, cyan square) and the thyroid
hormone T3 (orange) act as allosteric inhibitors and prevent the tetramer
adopting an active R-state conformation. The activator F16BP (green square)
clamps the tetramer in an enzymatically active conformation. (E) Addition of
F16BP to HCT-116 cells inhibits proliferation, whereas both inhibitors of M2PYK
(T3 and Phe) stimulate proliferation.
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Fig. 2. Oligomeric states of M1PYK and M2PYK. (A) Analytical gel-ﬁltration
elution proﬁle observed for 10-μL sample injection of 0.1 mg mL−1 M1PYK in
the absence (black) and presence (red) of 500 μM F16BP. (B) Same experi-
ment as in A but for M2PYK. (C) Determination of the molar mass of M2PYK
using SEC-MALS. Solid black line indicates the trace from the refractive index
detector, and red dots are the weight-averaged molecular masses for each
0.5-s slice analyzed. A total of 200 μg of M2PYK was injected onto
a Superdex 200 10/300 column. Flow rate was 0.5 mL min−1. (D) Concen-
tration response curves observed for the titration of PEP against M2PYK in
the presence (blue line) or absence (black line) of saturated F16BP. Error bars
are derived from three independent repeat experiments. (E) Analytical gel-
ﬁltration elution proﬁle observed for 10-μL sample injection of 0.1 mg mL−1
M2PYK in the absence (black) and presence (red) of 10 μM T3. (F) Analytical
gel-ﬁltration elution proﬁles observed for 10-μL sample injection of 0.5 mg
mL−1 M2PYK in the absence (black) and presence (red) of 5 mM Phe.
Experiments in which Phe was added to the running buffer could not be
monitored at 214 nm because Phe saturated the absorbance. Monitoring
M2PYK (that has a low extinction coefﬁcient) at 280 nm required a higher
M2PYK concentration, which increased lower limits from 0.1 mg/mL to 0.5
mg/mL. Thermal shift assays performed at 0.5 mg/mL M2PYK (Fig. S2) pro-
vide complementary results to those observed by gel ﬁltration.
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Vmax (Fig. S1C). (Note that the cellular concentration of PYK is
estimated to be in the region of 0.1 mg/mL or 2 μM (18), con-
siderably higher than the concentrations used for enzymatic
assays). The addition of F16BP stabilizes M2PYK in a pre-
dominantly enzymatically active tetrameric form (Fig. 2B),
and the 45% increase in tetramer concentration observed in
response to the addition of effector molecule correlates closely
with the increase in observed apparent Vmax (Table 1 and Fig.
2D). M2PYK enzymatic activity seems therefore to be regulated
in part by its ability to dissociate into inactive monomers.
Such a regulatory mechanism is a feature of so called V-type al-
losteric enzymes (19), but there are few well-characterized
V-type systems.
Monomer–Dimer–Tetramer Equilibrium and Enzyme Activity of M2PYK
(but Not M1PYK) Are Regulated by Allosteric Effectors, Including T3,
Phenylalanine, and F16BP.A selection of more than 50 metabolites
from the glycolytic, tricarboxylic acid cycle and pentose phosphate
pathways and other potential PYK modulators (amino acids,
oxalic acid, tartaric acid, and T3) were tested against both wildtype
(WT) M2PYK and M1PYK (Table S1). Several activators were
identiﬁed for M2PYK, which included F16BP (AC50 = 6.5 μM),
serine, and histidine, but none were identiﬁed for M1PYK. Only
phenylalanine, oxalic acid, and oxaloacetic acid were identiﬁed as
weak inhibitors for M1PYK, whereas several inhibitors were ob-
served for M2PYK, including phenylalanine, tryptophan, alanine,
and more weakly, oxalic acid and ribose 5-phosphate. Phenylala-
nine has an apparent IC50 of 0.24 mM for M2PYK (Table 2) and
exhibits signiﬁcantly poorer afﬁnity for M1PYK (IC50 >1 mM).
Phenylalanine demonstrates an interesting speciﬁcity against
M2PYK because similar molecules (tyrosine, dopamine, octop-
amine, 2-amino-1-phenylethanol, and tryamine) failed to elicit a
response. SEC was used to examine the effect of phenylalanine
on the oligomeric state of M2PYK, and it clearly stabilizes M2PYK
in a tetrameric form (Fig. 2F).
T3 contains the phenylalanine substructure and is known to in-
hibit the human cytosolic thyroid hormone-binding protein p58
(20), a mutant form of M2PYK found in human epidermoid car-
cinoma cells (20–22). We now show it to be a potent inhibitor of
M2PYK enzyme activity, with an IC50 = 72 nM (Table 2 and Fig.
S1). Again, T3was selective forM2PYKoverM1PYK. Intriguingly,
SEC showed that in contrast to phenylalanine, T3 inhibits tetramer
formation and stabilizes M2PYK monomers (Fig. 2E).
The stabilizing effects of PYK modulators were analyzed using
a thermal denaturation assay (Table 2 and Fig. S2). An increase in
melting temperature (Tm) reﬂects ligand binding and reduced
conformational ﬂexibility. The addition of the allosteric activa-
tor F16BP to M2PYK apoenzyme shows the most dramatic in-
crease in the Tm, from 48 °C to 55 °C. The addition of inhibitory
amino acids phenylalanine, alanine, and tryptophan resulted in
signiﬁcant increases in Tm values (2–4 °C). The addition of nor-
phenylephrine and T3 to M2PYK resulted in Tm shifts of 3 °C. At
identical concentrations, these ligands had no effect on the Tm of
M1PYK, conﬁrming the enzymatic results and the preference of
these ligands for binding to M2PYK over M1PYK.
X-Ray Structural Studies of R-State M1PYK, R-State M2PYK, and T-State
M2PYK. Peg-in-hole geometry locks M1PYK and active M2PYK in identical
conformations. Both the human unligated M1PYK and M2PYK
complexed with ATP, oxalic acid, and F16BP (M2PYK-ATP/OX/
F16BP; active R-state) were crystallized at a physiologically rele-
vant pH of 7.2 and the structures reﬁned at 2.85 and 2.55 Å
(Table S2), respectively. The R-state complex of M2PYK ATP/
OX/F16BP provides an example of a structure of a mammalian
allosteric PYK with ATP bound in the active site. The human
M1PYK structure presented here differs by 16 amino acid res-
idues from the previously published rabbit (2, 23) M1PYK
structures.
The M2PYK-ATP/OX/F16BP complex adopts a structure
(Fig. 3A) similar to that of constitutively fully activeM1PYK, with
an rms ﬁt for all Cα atoms (excluding the effector loops and the
ﬂexible B-domains) of ∼0.5 Å. The only region exhibiting any
signiﬁcant difference corresponds to the 22 amino acid splice
difference (Fig. 3 B and C) between M1PYK and M2PYK, which
makes up the “C-C” dimer interface between the C-domains in
the tetramer. Key differences in hydrogen bonding across the C-C
interface involve Lys421 (Fig. 3B). In the M1PYK structure, Cα1
and Cα2 helices form a tight clasp around Lys421, which makes
a salt bridge with Glu409 and three additional hydrogen bonds
with Ser401, Ser404, and Tyr443. In the M2PYK structure, the
backbone of the linker between the Cα1 and Cα2 helices (402Pro-
Ile-Thr-Ser-Asp-Pro407) adopts a signiﬁcantly different confor-
mation compared with the M1PYK linker (402Ser-His-Ser-Thr-
Asp-Leu407), which pushes the helices further apart by 2.5 Å. This
has the effect of relaxing the very tight peg-in-hole binding that was
observed in the M1PYK structure, in which Lys421 acts as the peg
and residues 390–420 form the hole (Fig. 3B).
Allosteric inhibitor phenylalanine locks the M2PYK tetramer in the T-state.
To probe the allosteric mechanism of M2PYK we made a mu-
tant, M2PYK-R489A. Replacement of Arg489 abolishes F16BP
binding and prevents contamination by F16BP, which is com-
monly bound during puriﬁcation of the protein from Escherichia
coli culture. M2PYK-R489A has within experimental error the
same S0.5(PEP) (0.77 ± 0.1 mM) as that of WT (0.86 ± 0.1 mM)
(Table 1). A complex of M2PYK-R489A with phenylalanine was
crystallized at pH 6.0 and the structure solved at a resolution of
2.9 Å (Table S2).
The phenylalanine complex adopts a T-state conformation in
which each of the protomers (comprising the A and C domains)
has rotated 13° from the active R-state M2PYK and M1PYK
structures described above. Phenylalanine binds in an allosteric
pocket located between the active and effector site (near the pivot
point where the rigid body rotation occurs; Fig. 4 A and B). The
T-state and R-state structures are shown in cartoon form in Fig. 1.
Table 1. Kinetic parameters for PEP
Protein
Apparent Vmax
(μmol per min per mg)
S0.5(PEP)
(mM) nH
M2PYK-WT 116.3 (3.3) 0.86 (0.08) 1.2
M2PYK-WT + 500 μM F16BP 212.9 (1.4) 0.10 (0.10) 1.0
M1PYK-WT 345.8 (12.8) 0.05 (0.05) 1.0
M1PYK-WT + F16BP 355.6 (11.5) 0.05 (0.05) 1.0
M2PYK-R489A 87.0 (3.9) 0.77 (0.11) 1.2
Errors shown in parentheses. SEs for nH are 0.1–0.2. Kinetic assays were car-
ried out at 37 °C at pH 7.4. Assay conditions: PBS (8.1 mM Na2HPO4, 1.5 mM
KH2PO4, 2.7 mM KCl, and 137 mMNaCl, pH 7.4) buffer with saturating [ADP] =
2 mM, [KCl] = 100 mM, and [MgCl2] = 10 mM in the presence or absence
of 500 μM of F16BP. PEP was serially diluted for 5 mM to 0.04 mM. The corre-
sponding kinetic data are shown in Fig. S1.
Table 2. Inhibition and thermal shift assays
Ligand
M2PYK-WT M1PYK-WT
AC/IC50 (μM) ΔTm (°C)* AC/IC50 (μM) ΔTm (°C)
F16BP 6.5 (0.3) 7 No effect No shift
Ser >1 mM 0 No effect No shift
His >1 mM 0 No effect No shift
Phe 240 (0.1) 4 >1 mM No shift
Nor 9,300 (1.9) 3 No effect No shift
T3 0.072 3 >4 μM No shift
Trp <1 mM 2 No effect No shift
Ala >1 mM 3 No effect No shift
Errors are in parentheses.
*Thermal shift assays were performed at pH 7.4 in PBS buffer using 0.5 mg/
mL of enzyme in the absence and presence of 1 mM ligand. The correspond-
ing thermal melt data are shown in Fig. S2.
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Rotation of the protomers pulls Lys421 out of its binding pocket
and destroys the peg-in-hole binding that stabilizes the C-C in-
terface in the R-state M2PYK structure (Movie S1).
The rigid body rotation of the protomers is similar to that
observed for the T to R transition in Leishmania mexicana PYK
(LmPYK) (24). In LmPYK the allosteric “rock-and-lock” regu-
lation mechanism is controlled by a concerted rigid-body rocking
motion of all four chains between an active (R) and inactive (T)
state, with the effector (in this case F26BP) locking the active
conformation by the formation of eight salt bridges across the
C-C interface of the tetramer. The locking mechanisms that
stabilize the R and T states are, however, very different between
the two species. In M2PYK the rigid body rotation of the pro-
tomers allows the side chains of Trp515 and Arg516 of the
(unoccupied) F16BP effector binding loop to swivel out and
form salt bridges and hydrogen bonds across the C-C interface,
stabilizing the tetramer in the inactive T-state. This conforma-
tion is further stabilized by the involvement of Trp515 and
Trp482 in a series of stacking interactions across the interface
(Fig. 4D and Movie S2).
Binding of the effector molecule F16BP causes the effector
loop (514–523) to fold up round the effector, forcing the side
chains of Trp515 and Arg516 to fold inward and breaking the T-
state stabilizing Arg516. . .Asp487. . .Trp515 hydrogen bond net-
work. The T-state-stabilizing hydrophobic stacking interactions
are also disrupted by a unique role for the indole ring nitrogen of
Trp482, which forms a hydrogen bond with the 1’-phospho group
of FBP (Fig. 4D).
The inhibitory allosteric effect of phenylalanine on PYK ac-
tivity has previously been reported, and a spectroscopic and bio-
chemical study on rabbit kidney PYK showed the poor inhibition
by phenylalanine of M1PYK relative to allosterically activated
PYK (25). A high-resolution X-ray structure of a complex of al-
anine with rabbit M1PYK has been shown to adopt a standard
R-state conformation that accommodates alanine bound in the
same site as the Phe-humanM2PYK structure but without dis-
torting the R-state conformation (26). It was also reported that
amino acids with larger side chains could not be crystallized in
complex with rabbit M1PYK, and this is consistent with the idea
that the tight peg-in-hole binding across the dimer interface in the
constitutively fully active M1 isoform is locking the R-state con-
formation, preventing entry of larger side chains into this newly
deﬁned phenylalanine allosteric pocket.
“Dock-rock-lock” model explains allosteric activation and inhibition of
M2PYK. The monomer-tetramer equilibrium of M2PYK, not ob-
served in any other of the trypanosomatid or mammalian PYK
isoforms, provides the ﬁrst step in the activation in which the
protomers “dock” together to form a tetramer (Fig. 1). The
equilibria here are controlled by protein concentration and al-
losteric effector molecules. The initial step in forming an active
complex is a docking across the C-C interface, which can be
stabilized in the R-state by the peg-in-hole interaction or in the
T-state by the Trp/Arg interactions as described in the phenyl-
alanine complex. As the protomers rock 13° from T- to R-state in
response to effector binding, the Trp-stabilized T-state inter-
actions are broken and the disordered Lys421 (the peg) slots into
the hole (formed by residues 390–420), thereby stabilizing the
R-state (Fig. 3 A and B and Movies S1 and S2).
The concerted rocking motion of each of the protomers explains
at the molecular level how the effector molecule F16BP can bind
over 40 Å away from the active site and enhance enzyme activity.
This motion is therefore similar in a number of ways to the rock-
and-lock mechanism of LmPYK, although the residues involved in
locking the protomers in a given T or R state are not conserved
between the species. The 13° rigid body “rock” of M2PYK places
Arg342 in position to prime the active site by stabilizing the short
glycine-rich A6’ helix (295Gly-Asp-Leu-Gly-Ile-Glu-Pro301) of an
adjacent protomer (Fig. S3). The involvement of adjacent proto-
mers in shaping the active site provides a clear explanation for the
inactivity of monomeric PYK and also therefore an explanation of
the inhibitory effect of T3, which stabilizes monomeric M2PYK.
Inhibition of M2PYK by Phenylalanine and T3 Enhance Cell Proliferation.
M2PYK is frequently up-regulated in cancer cells (27), and it has
been suggested that inactivating M2PYK would block metabolic
ﬂux, allowing build-up of glycolytic intermediates for macromo-
lecular biosynthesis and tumor growth (28, 29). The structural
and biochemical results described above provide mechanisms for
phenylalanine, T3, and F16BP to act as allosteric inhibitors and
activators with a high speciﬁcity for M2PYK over M1PYK. It was
of interest therefore to determine whether these compounds
would have an effect on cell growth.
We selected the cell line HCT-116 for this study because it
is known to overexpress M2PYK (30). Addition of 5 mM Phe
or 20 μM T3 to the cell culture media signiﬁcantly increased
cell proliferation compared with vehicle treated cells, whereas
A B
C
Fig. 3. M1PYK forms a tighter C-C interface than
M2PYK. (A) The M2PYK tetramer is shown with the
active and effector sites indicated. The bottom right
chain has been colored to aid the identiﬁcation of
domains: domain-A (blue = residues 25–116 and
220–402), domain-B (gray = residues 117–219), and
domain-C (red = residues 403–531). The large (A-A)
and small (C-C) interfaces between monomers are
shown as dashed lines. (B) Enlarged view of the di-
mer interface showing a comparison of the M1PYK
andM2PYK side chains. M1PYK hydrogen bonds are
shown in red and those of M2PYK in black (1).
Gln439 is repelled by Met408 in M1PYK allowing
Glu409 to form a salt bridge with Lys421 (2). (3) Cα2
of M1PYK is 2.5 Å closer to Lys421 than Cα2 of
M2PYK. (C) Splice variant amino acids between
M1PYK and M2PYK.
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addition of 1 mM F16BP resulted in complete inhibition of cell
growth (Fig. 1E). It has previously been shown that although
F16BP is highly negatively charged it can enter the cell (31).
In vitro the enzymatic inhibition of p58 by T3 can be overcome
by addition of high concentrations of F16BP (20). Another study
showed a similar effect, with inhibition by phenylalanine (25). We
were able to show comparable effects in cellular proliferation
experiments, whereby the addition of 1 mM F16BP was able to
abrogate the effects of both T3 and phenylalanine (Fig. 1E),
providing strong evidence that M2PYK is indeed the cellular
target. Together these data suggest that allosteric M2PYK acti-
vation can play a dominant role in regulating cancer cell growth.
There is increasing interest in M2PYK as a potential anti-
proliferative drug target, and stimulation of M2PYK activity (32–
34) or inhibition (17) have both been explored. The reduction in
size of tumor allografts observed using synthetic activators of
M2PYK (34) ﬁt with our observations that activation of M2PYK
leads to the inhibition of proliferation of HCT-116 cells and
supports the approach of developing small-molecule M2PYK
activators for cancer therapy.
M2PYK as a Nutrient Sensor and Regulator of Cell Proliferation. In
this article we have described the detailed regulatory mecha-
nisms of three small-molecule inhibitors and activators. The
structural and biophysical data describe two molecular mecha-
nisms for inhibiting M2PYK, as summarized in Fig. 1. T3 traps
M2PYK in an inactive monomeric state, whereas phenylalanine
traps M2PYK in an inactive tetrameric T-state. Despite these
different inhibitory mechanisms each inhibitor has similar dra-
matic effects on cellular proliferation, suggesting that their
interactions with M2PYK are biologically relevant.
There is a large body of published work on the biological roles
of T3 (35). The most studied properties of thyroid hormones
relate to their activities as gene regulators. However, there is
a pool of unbound T3/T4 available at approximately nanomolar
concentration (36), which regulates a number of nongenomic
actions. In two breast cancer cell lines, increased T3 levels cor-
relate with the degree of Warburg phenotype and increased level
of M2PYK (36).
F16BP is effective in reducing the tissue damage associated with
ischemia due to hypo-perfusion, and at concentrations in the mil-
limolar range F16BP suppresses T-cell proliferation (37), which
provides a potential therapy against inﬂammation and sepsis.
Tyrosine phosphorylation has been shown to prevent binding of
F16BP, thus preventing enzyme activation, and the ability of
M2PYK to bind F16BP was inversely correlated with tumor growth
in xenograft mice (38). In this context F16BP binding to M2PYK
is acting as an inhibitor of cell proliferation, which correlates with
our result.
Several reviews have mentioned that amino acids affect hu-
man M2PYK activity but without detailed kinetic data (6, 29),
and one study on rabbit kidney PYK showed the poor inhibition
by phenylalanine of rabbit M1PYK relative to allosterically ac-
tivated PYK (25). The effect of phenylalanine on cancer cell
proliferation has not been previously published, although in
some early work a phenylalanine restricted dietary regimen has
been shown to result in signiﬁcant inhibition of tumor growth in
mice (39, 40). It is compelling that phenylalanine and T3, which
inhibit M2PYK enzyme activity, both show the same cellular
phenotype in HCT-116 cells. Interestingly, earlier work showed
that the effect of T3 on epithelial cell replication can be replaced
by phenyalanine, and transformation strongly reduces both T3
and phenylalanine requirements for growth (41).
Phenylalanine is one of the essential amino acids and cannot be
synthesized by mammals and requires constant monitoring. The
allosteric pocket identiﬁed in the M2PYK-Phe crystal structure
may therefore provide a potential feedback mechanism to block
enzyme activity when phenylalanine is abundant in the cell,
allowing metabolite build-up and cell proliferation. The various
oligomeric states of M2PYK described here (Fig. 1) suggest how
M2PYK may be acting as a complex nutrient sensor for the cell,
responding directly or indirectly to ﬂuctuations in oxygen (11),
essential amino acids, hormones, and glucose.
Materials and Methods
M1PYK and M2PYK Production and Activity Measurements.M1PYK and M2PYK
were expressed and puriﬁed as described in SI Materials and Methods. Site-
directed mutagenesis of M2PYK cDNA was performed using the Quik-
Change mutagenesis kit from Stratagene, according to the manufacturer’s
instructions. Enzyme activity measurements in the absence and presence
of modulators were performed using the standard lactate dehydrogenase
coupled assay (SI Materials and Methods).
Crystallization and Structure Determination. Single crystals of M1PYK and
M2PYK were obtained as described in SI Materials and Methods, and dif-
fraction data were collected at the Diamond synchrotron radiation facility in
Oxfordshire, United Kingdom on beamline IO3 to a resolution of 2.55 Å
(M2PYK-ATP/OX/F16BP), 2.9 Å (M2PYK-R489A-Phe), and 2.85 Å (M1PYK). All
datasets were obtained from a single crystal ﬂash-frozen in liquid nitrogen
at 100 K. Structures were solved by molecular replacement as described in SI
Materials and Methods. Atomic coordinates and the experimental structure
factors for all structures have been deposited in the Protein Data Bank, with
the following codes, M1PYK (3SRF), M2PYK-ATP/OX/F16BP (4FXF), and
M2PYK-R489A-Phe (4FXJ).
A B
C D
Fig. 4. Allosteric inhibitor phenylalanine locks the M2PYK tetramer in the T-
state. All ligands and interacting amino acids are shown as sticks; hydrogen
bonds are shown as dashed red lines. The resolution of the electron density (Fo-
Fc map, shown in green) map is 2.9 Å and is contoured at 3σ. (A) A cartoon
representation of the T-state tetramer (M2PYK-Phe). (B) Enlargement of the
Phe binding site. (C ) Side view (rotated 90° to that of A) of the superposed
R-state (M2PYK-ATP/OX/F16BP) and T-state structures (M2PYK-Phe). (D)
Enlargement of the C-C interface highlighting conformational changes and
side chain movements (arrows) as the protomers rotate from R- (effector
bound) to T- (Phe bound) state.
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Analytical Gel Chromatography. M1PYK and M2PYK were puriﬁed under
identical conditions, and highly puriﬁed samples of both isozymes were
loaded independently onto a Superdex 200 PC 3.2/30 gel-ﬁltration column.
Unless stated otherwise, protein samples were analyzed at physiologically
relevant concentrations (0.1 mg/mL) (18). Ten-microliter samples were injec-
ted, and the column ﬂow rate was maintained at 0.1 μL min−1. Separations
and equilibration steps were performed in PBS without calcium and mag-
nesium (PBS-CM) or PBS-CM supplemented with the appropriate concentra-
tion of F16BP, T3, or phenylalanine at 26 °C. Protein peaks were monitored
using absorbance at both 280 and 214 nm. All samples were incubated
overnight at 26 °C before analysis.
SEC-MALS Analysis. SEC was carried out at room temperature at a ﬂow rate of
0.5 mL min−1 using a Superdex 200 10/300 GL. The Superdex column was
connected in-line with the following detectors; UV detector, a light scat-
tering detector (Wyatt Technology), and a refractometer.
Thermal Shift Assay. Thermal shift assays were performed essentially as de-
scribed previously (24), except PBS buffer was used throughout.
Cell Growth Experiments. HCT-116growing (37 °C and 5%CO2) exponentially in
McCoy’s 5A media plus 10% FCS (MS) were suspended with trypsin EDTA
(trypsin, 0.05%; EDTA, 0.02%), and ∼32,000 cells per well (1.6 mL of 20,000 cells
per mL) were plated into sterile six-well (35-mm) plastic culture dishes. After
sufﬁcient time for the cells to become adherent had elapsed (12–16 h) an
Alamar blue assay (Invitrogen) was performed to ensure equivalent cell density
between wells as per the manufacturer’s instructions. The medium was
changed (1.6 mL ofmedia perwell) toMcCoy’s 5Amedia plus 10%dialyzed FCS
(Dundee Cell Products, catalog no. DS1002) supplemented with either T3 (a 25-
mM stock solution was prepared in 100 mM NaOH), F16BP (a 100-mM stock
solution was prepared in McCoy’s 5A media, and the pH adjusted to 7.4 with
NaOH or phenylalanine (an 80-mM stock solution was prepared in McCoy’s 5A
media). All ligand stocks were ﬁltered through a 0.2-μm ﬁlter. Cells were then
grown for a further 72 h and were collected by suspension in trypsin-EDTA and
counted in a hemocytometer. Ligands used in this study interfere with meta-
bolic pathways (TCA and glycolysis), leading to difﬁculties interpreting meta-
bolic-based proliferation assays.
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